Long term remission with 6-Mercaptopurine in refractory Evans syndrome

Illias Tazi, Hatim Nafil, L. Mahmal
In: The Journal of Cancer Research · 2011 · vol. 3(2) , pp. 20–21 · doi:10.5897/jcreo.9000017 · W2111293632
article OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-07, 2026-07-14 ⓘ

This case report details a 35-year-old female patient who achieved long-term remission of refractory Evans syndrome using 6-mercaptopurine.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-07, 2026-07-14 · read from full text ⓘ

This short communication reports a long-term remission of Evans syndrome in a 35-year-old female treated with 6-mercaptopurine after refractoriness and typical challenges such as initial treatment failure and later relapses seen with Evans syndrome. The paper describes the clinical outcome as sustained remission with 6-mercaptopurine as a second-line option. A key limitation is that the report is a single-patient case report, with no broader population-based data or comparative analysis. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

The management of Evan’s syndrome remains a challenge and innovative approaches are needed. Initial therapeutic failure, relapses after initial response and refractoriness to treatments are typical. Options for second-line therapy include immunosuppressive drugs, especially cyclosporin or mycophenolate mofetil; vincristine; danazol or a combination of these agents. We report here a long-term remission of Evan’s syndrome obtained with 6-mercaptopurine in a 35-year-old female patient.   Key words: 6-Mercaptopurine, Evan’s syndrome, remission.
Full text 1,629 characters · extracted from oa-html · click to expand
Cancer Research and Experimental Oncology - Abbreviation: J. Cancer Res. Exp. Oncol. - Language: English - ISSN: 2141-2243 - DOI: 10.5897/JCREO - Start Year: 2009 - Published Articles: 59 Short Communication - Hematology Department, Chu Mohamed VI, University Cadi Ayyad, Marrakech, Morocco. - Search for this author on: - Google Scholar - Hematology Department, Chu Mohamed VI, University Cadi Ayyad, Marrakech, Morocco. - Search for this author on: - Google Scholar - Hematology Department, Chu Mohamed VI, University Cadi Ayyad, Marrakech, Morocco. - Search for this author on: - Google Scholar - Article Number - 0B114013971 - Vol.3(2), pp. 20-21 , February 2011 - https://doi.org/10.5897/JCREO.9000017 - Accepted: 25 January 2011 - Published: 28 February 2011 Copyright © 2026 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution License 4.0. Abstract The management of Evan’s syndrome remains a challenge and innovative approaches are needed. Initial therapeutic failure, relapses after initial response and refractoriness to treatments are typical. Options for second-line therapy include immunosuppressive drugs, especially cyclosporin or mycophenolate mofetil; vincristine; danazol or a combination of these agents. We report here a long-term remission of Evan’s syndrome obtained with 6-mercaptopurine in a 35-year-old female patient. Key words: 6-Mercaptopurine, Evan’s syndrome, remission. Copyright © 2026 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution License 4.0

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (6)

Source provenance

openalex
last seen: 2026-05-10T10:13:55.754549+00:00
License: CC0 · commercial use OK